A Phase I Clinical Study to Evaluate the Effect of GZR18 Injection on the Pharmacokinetics of Oral Metformin Hydrochloride Tablets in Overweight/Obese Subjects

Phase 1 Not yet recruiting 32 enrolled Gan and Lee Pharmaceuticals, USA

NaSingle-groupOpen-labelTreatment

Summary

This is a single-center, open-label, fixed-sequence phase I clinical study to evaluate the effect of multiple subcutaneous injections of GZR18 Injection on the pharmacokinetics of multiple oral doses of metformin hydrochloride tablets.

Timeline

Start: 2024-10-30
Primary completion: 2025-03-19
Completion: 2025-03-19

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Bofanglutide	Protein / enzyme biologic	3 mg	Subcutaneous
Subject	Bofanglutide	Protein / enzyme biologic	18 mg	Subcutaneous
Subject	Metformin	Small molecule	500 mg	Oral

A Phase I Clinical Study to Evaluate the Effect of GZR18 Injection on the Pharmacokinetics of Oral Metformin Hydrochloride Tablets in Overweight/Obese Subjects

Summary

Timeline

Drugs

Indications